Company News

GMet’s Integrated Omics Technology Platform Used in Study that Demonstrates Restoration of Energetic and Structural Function in ARVC Utilizing AAV9-PKP2 Gene Therapy

GMet’s Integrated Omics Technology Platform Used in Study that Demonstrates Restoration of Energetic and Structural Function in ARVC Utilizing AAV9-PKP2 Gene Therapy

General Metabolics Opens New US-based Laboratory in Boston

General Metabolics (GMet) is excited to announce the opening of its new U.S.-based laboratory in Boston, Massachusetts. After previously operating out of the ETH in Zurich, Switzerland, metabolomics studies from our U.S. and international clients will now be handled exclusively by GMet’s Boston laboratory.

General Metabolics’ Boston Laboratory Contracts Over 10,000 Samples

General Metabolics (GMet) is excited to report that as of February 2020 it has contracted over 10,000 samples for non-targeted metabolomics analysis at its Boston laboratory.

General Metabolics is Partnering with Dana Farber Cancer Institute

GMet is incredibly pleased to share the initial announcement of our partnership with Dana Farber Cancer Institute to create a state-of-the-art metabolomics facility at their Longwood site, providing on-campus access to GMet technologies for DFCI and Harvard researchers, and remote access to academic researchers world-wide.